August 27, 2020/Cancer

High-Volume Plasma Exchange in a Young COVID-19 Patient with Liver Failure

Bridge to transplant after acetaminophen overdose

650×450-Plasma

In June 2020, a 27-year-old woman developed a case of COVID-19; her main symptoms were stomach pain, nausea and diarrhea. To relieve the pain, she took so much acetaminophen that she had an overdose and developed fulminant liver failure.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

She was gravely ill and hospitalized at Cleveland Clinic in the COVID ICU. She was intubated and treated for symptoms of liver failure, which included cerebral edema.

To normalize her blood pressure, she was treated with high-dose vasopressors. The liver failure also caused a cytokine storm, which stressed her heart and kidneys. She was in need of a liver transplant but was considered too high risk. “Every moment, she was getting worse and further from being able to get a liver transplant,” says Kristin Ricci, MD, a transfusion medicine specialist and Medical Director of the apheresis unit at Cleveland Clinic.

High-volume plasma exchange administered

Cleveland Clinic is one of only a few medical centers worldwide able to perform high-volume plasma exchange. During the procedure, a patient’s plasma is removed with an apheresis instrument and is replaced with plasma from healthy donors. Unlike standard plasma exchange treatments, which treat a patient’s plasma once, high-volume plasma exchange treats it three to four times. This patient was the first at Cleveland Clinic treated with this approach; the goal was to stabilize her health so she could get a transplant.

Advertisement

The procedure was a team effort involving intensive care, hepatology, anesthesiology, liver transplant, nursing, apheresis, laboratory medicine and blood bank teams. “High-volume plasma exchange requires great resources and coordination. Many different groups used their strengths to save this patient’s life — Cleveland Clinic culture at its best,” says Dr. Ricci.

After the procedure, the patient became more hemodynamically stable, her vasopressor requirements decreased and many of her liver labs normalized. The procedure also removes inflammatory cytokines, so the storm subsided. Because of these major improvements, the patient was listed for a liver transplant.

The liver transplant team, led by Giuseppe D’Amico, MD, and Jacek Cywinski, MD, was ready to perform the transplant. The next day, the patient received a second high-volume plasma exchange which showed continued improvement in clinical status and labs. The transplant was performed that evening by a team that included more than 40 caregivers.

Advertisement

A life transformed

The patient had an uneventful recovery and has been discharged home and is doing well. “The high-volume plasma exchange was a game changer that saved her life. This technique completely changed the management strategy for this patient. We are excited about starting a program to use high-volume plasma exchange for acute liver failure,” says Cristiano Quintini, MD, Program Director and Surgical Director of the Liver Transplantation Program.

Related Articles

Women's health physician
April 16, 2024/Cancer
Watching Out for Primary Ovarian Insufficiency

An underdiagnosed condition in patients with cancer

Fluorescent imaging during small bowel surgery
April 11, 2024/Cancer/Surgical Oncology
Fluorescence Imaging Augments Surgical Inspection and Palpation for Small Bowel Carcinoid Tumors

Study demonstrates superior visualization of occult primary lesions

microwave ablation of liver tumor
150-Watt, Single-Antenna Microwave Ablation System Demonstrates Safety and Efficacy

New device offers greater tumor control for malignant liver lesions

viral-induced cancer
April 3, 2024/Cancer
Mechanism of Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) May Serve as Clue to More Effective Treatment

Cleveland Clinic researchers discover what drives – and what may halt – virus-induced cancer

Dr. Mukherjee at Cleveland Clinic
April 1, 2024/Cancer/Blood Cancers
Many Patients with “Indolent” Systemic Mastocytosis Experience Rapid Decline and Lower Survival

First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention

Cleveland Clinic physiatrist
March 22, 2024/Cancer/Innovations
The Vital Role of Oncology Rehabilitation (Podcast)

New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Ad